Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Bright Minds Biosciences Inc. (DRUG : NSDQ)

• Company Description    Bright Minds Biosciences is a biotechnology company. It focused on developing novel drugs for targeted treatment of neuropsychiatric disorders, epilepsy and pain. Bright Minds Biosciences is based in VANCOUVER, British Columbia. Number of Employees: 25

• Price / Volume Information    Yesterday's Closing Price: $83.50 Daily Weekly Monthly 20 Day Moving Average: 226,720 shares Shares Outstanding: 9.73 (millions) Market Capitalization: $812.64 (millions) Beta: -5.35 52 Week High: $123.75 52 Week Low: $23.18 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -5.84% -10.44% 12 Week -2.34% -9.72% Year To Date 7.00% -1.94%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 400 N ABERDEEN ST SUITE 900 - CHICAGO,IL 60642 USA ph: 64-7407-2515 fax: - lwilson@insitecony.com https://brightmindsbio.com

• General Corporate Information    Officers Ian McDonald - Chief Executive Officer and Director Alex Vasilkevich - Chief Operating Officer Ryan Cheung - Chief Financial Officer Jeremy Fryzuk - Director Nils Bottler - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 10919W405 SIC: 2834 Fiscal Year Fiscal Year End: September Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/13/26 Share - Related Items Shares Outstanding: 9.73 Most Recent Split Date: 7.00 (0.20:1) Beta: -5.35 Market Capitalization: $812.64 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.36 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-4.99 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/13/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 3.61 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -175.86% vs. Previous Quarter: -14.29% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/26 - -20.58 12/31/25 - -28.62 09/30/25 - -19.92 ROA 03/31/26 - -20.25 12/31/25 - -28.08 09/30/25 - -19.57 Current Ratio 03/31/26 - 81.47 12/31/25 - 57.38 09/30/25 - 36.09 Quick Ratio 03/31/26 - - 12/31/25 - 57.38 09/30/25 - 36.09 Operating Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Net Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Pre-Tax Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Book Value 03/31/26 - 23.11 12/31/25 - 6.58 09/30/25 - 8.33 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - 0.00 12/31/25 - 0.02 09/30/25 - 0.05

Powered by Zacks Investment Research ©